MREO News and Press, Mereo BioPharma Group From 10/17/22

The U.S. Food and Drug Administration (FDA) granted fast track designation to Mereo BioPharma alvelestat (MPH-966) to treat Alpha-1 Antitrypsin Deficiency (AATD)-associated lung disease. The London-based company said it plans to have an end-of-phase 2 meeting with th...

Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022 LONDON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“M...

Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board Mereo Reiterates Support for its Experienced, Highly Qualified Board and Urges Shareholders to Reject Rubric...

Rubric Capital Management has boosted the number of nominees it is backing for Mereo BioPharma ( NASDAQ: MREO ) to five . The fifth nominee is Rubric founder David Rosen. In a letter to shareholders, Rosen wrote that "the problems on the Board of Mereo ( MREO )...

Director Nominees Possess the Financial, Regulatory and Strategic Expertise to Maximize Value for All Shareholders Details Mereo’s Desperate Efforts to Thwart Requisition of General Meeting of Shareholders Rubric Capital Management LP (“Rubric&#...

Rubric Capital Management rejected an offer from Mereo BioPharma Group ( NASDAQ: MREO ) to put a Rubric principal and another director on the company's board. Mereo ( MREO ) also said its offer included having two of its current board member retire. The biotech...

Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer Rubric’s Second General Meeting Requisition Notice Again Fails to Satisfy Basic Requirements of the Companies Act 2006 Which Apply to All U.K. Companies and Shareholders LONDON, Sept. 26,...

Summary This is an update on the previously written report on Mereo BioPharma Group, a London-based clinical-stage biopharma. Frustrated with the lack of engagement from the management, the activist filled a request for a special shareholder meeting aiming to replace 4 incumbent d...

Rubric Capital Management submitted a revised requisition to Mereo BioPharma's ( NASDAQ: MREO ) board for a general meeting of shareholders. Rubric — which claims to own ~14% stake in Mereo — issued an open letter on Sept. 14 criticizing th...

Submits Revised Requisition for General Meeting of Shareholders Condemns Company’s Governance and Corrects the Record on Mereo’s Misleading Public Statements Rubric Capital Management LP (“Rubric”), an investment advisor whose fund...